Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cov-RBD-scNP-001
- Development stage
- Phase 1
- Lead developer
- Duke University
- Modality
- Nanoparticles → Drug Delivery Systems, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**Cov-RBD-scNP-001** is an investigational adjuvanted pancoronavirus protein-nanoparticle vaccine developed by Duke University for prevention of COVID-19 and potentially broader protection against SARS-related betacoronaviruses. Its immunogen comprises an engineered SARS-CoV-2 WA-1 receptor-binding domain covalently displayed on a *Helicobacter pylori* ferritin nanoparticle; the 24-subunit ferritin scaffold can present multiple RBD copies through a nine-amino-acid linker. It is administered with the TLR7/8 agonist adjuvant 3M-052-AF to enhance innate and adaptive antiviral immune responses, including neutralizing antibodies directed at the SARS-CoV-2 spike RBD.
- Other names
- RBD-scNP
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on Cov-RBD-scNP-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cov-RBD-scNP-001.